Patents by Inventor Jonathan F. Smith

Jonathan F. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12280102
    Abstract: Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: April 22, 2025
    Assignee: VLP Therapeutics, Inc.
    Inventors: Wataru Akahata, Jonathan F. Smith, Ryuji Ueno
  • Publication number: 20240401081
    Abstract: Provided herein is a novel immunologically-active alphavirus replicon vector which comprises a nucleic acid encoding alphavirus nonstructural proteins nsp1-4 and a cytokine protein(s)/polypeptide(s), which is useful for the treatment of a cancer and/or an inflammatory disease.
    Type: Application
    Filed: August 19, 2024
    Publication date: December 5, 2024
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH
  • Patent number: 12134777
    Abstract: Provided herein is a novel immunologically-active alphavirus replicon vector which comprises a nucleic acid encoding alphavirus nonstructural proteins nsp1-4 and a cytokine protein(s)/polypeptide(s), which is useful for the treatment of a cancer and/or an inflammatory disease.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: November 5, 2024
    Assignee: VLP Therapeutics, Inc.
    Inventors: Wataru Akahata, Jonathan F. Smith
  • Publication number: 20240335528
    Abstract: ABSTRACT OF DISCLOSURE Provided herein is a bivalent alphavirus replicon vaccine, which is a combination of a first polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and an antigenic peptide and a second polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a CD8+ T cell epitope. The vaccine is useful against virus infection, especially, COVID-19 or SARS-COV-2 infection, the treatment of a cancer and/or an inflammatory disease.
    Type: Application
    Filed: June 21, 2024
    Publication date: October 10, 2024
    Applicant: VLP Therapeutics Japan, Inc.
    Inventors: Wataru Akahata, Jonathan F. Smith, Jeffery Leo Alexander, Takashi Sekida
  • Publication number: 20230201333
    Abstract: Provided herein is an isolated polynucleotide, which encodes structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising an antigenic protein fused to a signal sequence, a transmembrane domain and at least one peptide selected from CD4+ T cell epitopes and CD8+ T cell epitopes. The polynucleotide is useful for manufacturing a vaccine against virus infection, especially, COVID-19 infection, the treatment of a cancer and/or an inflammatory disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 29, 2023
    Applicant: VLP Therapeutics Japan, LLC
    Inventors: Wataru AKAHATA, Jonathan F. SMITH, Jeffery Leo ALEXANDER, Takashi SEKIDA
  • Publication number: 20210340567
    Abstract: Provided herein is a novel immunologically-active alphavirus replicon vector which comprises a nucleic acid encoding alphavirus nonstructural proteins nsp1-4 and a cytokine protein(s)/polypeptide(s), which is useful for the treatment of a cancer and/or an inflammatory disease.
    Type: Application
    Filed: April 28, 2021
    Publication date: November 4, 2021
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH
  • Publication number: 20210322541
    Abstract: Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 21, 2021
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH, Ryuji UENO
  • Patent number: 10570416
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: February 25, 2020
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 10434187
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector of replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: October 8, 2019
    Assignee: APHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • Patent number: 10111943
    Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 30, 2018
    Assignee: ALPHAVAX, INC.
    Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
  • Publication number: 20180050118
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector of replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Application
    Filed: March 15, 2017
    Publication date: February 22, 2018
    Inventors: Vernon McNeil COFFIELD, III, Kurt I. KAMRUD, Jonathan F. SMITH
  • Patent number: 9597414
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: March 21, 2017
    Assignee: ALPHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • Publication number: 20160375124
    Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Application
    Filed: June 29, 2016
    Publication date: December 29, 2016
    Inventors: Jonathan F. SMITH, Bolyn Hubby, Laura Copp
  • Publication number: 20160348132
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
  • Patent number: 9441247
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 13, 2016
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 9416370
    Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: August 16, 2016
    Assignee: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
  • Publication number: 20150299728
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: July 6, 2015
    Publication date: October 22, 2015
    Inventors: Jon O. RAYNER, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 9079943
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 14, 2015
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Publication number: 20140308312
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Application
    Filed: February 5, 2014
    Publication date: October 16, 2014
    Applicant: ALPHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • Publication number: 20140205629
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 24, 2014
    Applicant: AlphaVax, Inc.
    Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP